Operating in Ireland since 1935, Johnson & Johnson is one of Ireland’s leading employers, with a workforce of more than 5,000 highly skilled and motivated people across 10 locations, spanning ...

Michaela Hagenhofer, General Manager, Commercial Operations at Johnson & Johnson Innovative Medicine, explains how J&J is ...

Johnson & Johnson raised its full-year sales forecast today after beating estimates for second-quarter profit on strong demand for its cancer drug, Darzalex, and strength in its medical device ...

Johnson & Johnson (NYSE: JNJ) announced today new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY® (talquetamab-tgvs), the first U.S. Food and Drug ...

Johnson & Johnson Senior Vice President and Group CIO of Global Supply Chain, Steve Wrenn, sat down with Transform to share his perspective on the ways Johnson & Johnson uses the capabilities of the ...

Johnson & Johnson (NYSE: JNJ) revenue grew at a CAGR of 4.1% from $70.0 billion in 2015 to $82.0 billion in 2019, and it is estimated to top $85 billion in 2020, led by its pharmaceuticals ...

Johnson & Johnson’s new identity is intended to reflect wider changes in the company, which now has an “exclusive focus on healthcare innovation and tackling the toughest health challenges”. The ...